Trial Profile

Clinical study of SIM 0237

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 01 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SIM-0237 (Primary)
Indications Solid tumours
Focus Adverse reactions

Most Recent Events

01 Nov 2022 New trial record
27 Oct 2022 According to a Simcere Pharmaceutical Group media release, the IND application of SIM0237 in China was accepted by the National Medical Products Administration.
10 Oct 2022 According to a Simcere Pharmaceutical Group media release, the company has submitted clinical trial (IND) applications to China National Medical Products Administration (NMPA) and approval is expected in January 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com